Jazz Pharmaceuticals plc
JAZZ · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $4.27B | $4.07B | +4.9% |
| Operating income | −$430M | $717M | |
| Net income | −$356M | $560M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $1.24B | $1.13B | +10.4% |
| Operating income | −$413M | $57.5M | |
| Net income | −$483M | $251M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Jazz Pharmaceuticals's revenue in FY2025?
- $4.27B in FY2025 (Fiscal year ended Dec 31, 2025), +4.9% vs $4.07B a year earlier, per its 10-K filed Feb 2026.
- Was Jazz Pharmaceuticals profitable in FY2025?
- No: net income was −$356M and operating income −$430M in FY2025.
- What was Jazz Pharmaceuticals's revenue in Q3 2026?
- $1.24B (+10.4% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.